These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 34696564)

  • 1. Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials.
    Yin Q; Dai L; Sun R; Ke P; Liu L; Jiang B
    Cancer Res Treat; 2022 Jul; 54(3):803-816. PubMed ID: 34696564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.
    Gu J; Shi L; Jiang X; Wen J; Zheng X; Cai H; Zhang W
    Cancer Immunol Immunother; 2022 Sep; 71(9):2239-2254. PubMed ID: 35124713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
    Siciliano MA; Caridà G; Ciliberto D; d'Apolito M; Pelaia C; Caracciolo D; Riillo C; Correale P; Galvano A; Russo A; Barbieri V; Tassone P; Tagliaferri P
    ESMO Open; 2022 Jun; 7(3):100465. PubMed ID: 35427835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
    Shao T; Zhao M; Liang L; Tang W
    Front Immunol; 2022; 13():948597. PubMed ID: 36389713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis.
    Armoiry X; Tsertsvadze A; Connock M; Royle P; Melendez-Torres GJ; Souquet PJ; Clarke A
    PLoS One; 2018; 13(7):e0199575. PubMed ID: 30044785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
    World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
    Peng TR; Lin HH; Tsai FP; Wu TW
    Thorac Cancer; 2021 Nov; 12(21):2873-2885. PubMed ID: 34545685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
    Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
    Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
    Zhang W; Gu J; Bian C; Huang G
    Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
    [No Abstract]   [Full Text] [Related]  

  • 13. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
    Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.
    Li J; Chen Y; Hu F; Qiang H; Chang Q; Qian J; Shen Y; Cai Y; Chu T
    Front Oncol; 2022; 12():1001503. PubMed ID: 36523992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma.
    Chen HL; Tu YK; Chang HM; Lee TH; Wu KL; Tsai YC; Lee MH; Yang CJ; Hung JY; Chong IW
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
    Schulz C; Gandara D; Berardo CG; Rosenthal R; Foo J; Morel C; Ballinger M; Watkins C; Chu P
    Clin Lung Cancer; 2019 Nov; 20(6):451-460.e5. PubMed ID: 31375454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
    Liu T; Wu S; Fang W; Li H; Su L; Qi G; Li H; Liu Y
    PLoS One; 2023; 18(4):e0283719. PubMed ID: 37071610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
    Medicine (Baltimore); 2018 Aug; 97(33):e11936. PubMed ID: 30113497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
    Pang LL; Gan JD; Huang YH; Liao J; Zhuang WT; Ali WA; Hong SD; Zhang L; Fang WF
    BMC Cancer; 2023 Jan; 23(1):72. PubMed ID: 36670414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.